Dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of advanced melanoma

Introduction

Dabrafenib (trade name: Tafinlar) and trametinib (trade name: Mekinist) have been approved in Germany since 2013 and June 2014 respectively for the treatment of melanoma in adults that can't be surgically removed or that has already formed distant metastases. They have also been approved for use in combination with each other since 2015. Since August 2018, the combination has also been approved for use as supportive (adjuvant) therapy after surgery to remove melanoma that had spread to the lymph nodes. These medications – alone, or in combination with each other – are options for people who have a mutated protein in their tumor tissue (BRAF V600 mutation) that can lead to uncontrolled tumor growth.

Melanoma is the most dangerous type of skin cancer. It starts growing in the cells that produce the dark pigment in skin. Melanomas are usually surgically removed. But they are sometimes too large to be removed or may have spread to other parts of the body (metastatic tumors) through the blood or lymphatic system. If this happens, it is called advanced melanoma.

Dabrafenib aims to inhibit the mutated protein in order to prevent tumor growth, while trametinib blocks an alternative signal route, also stopping tumor growth.

Application

Dabrafenib is taken as a tablet (150 mg) every morning and evening, about one hour before or at least two hours after a meal. The two doses should be taken about 12 hours apart.

Trametinib is taken once a day as a tablet (2 mg).

The treatment is stopped if the disease progresses or if dangerous side effects arise. In adjuvant therapy, the treatment lasts twelve months. Here too, treatment is stopped if the disease comes back or if dangerous side effects arise.

Other treatments

At the time of the 2015 assessment, the drug vemurafenib was the standard treatment for adults who have melanoma that can't be removed surgically or has formed distant metastases.

After the complete surgical removal of melanoma with a BRAF V600 mutation and metastases in the lymph nodes, the standard treatment is watchful waiting: Patients are examined regularly in order to detect and treat any recurrence early on.

Assessment

In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether the combination of dabrafenib and trametinib, when compared with vemurafenib, has any advantages or disadvantages for people with advanced melanoma that can't be surgically removed or has formed distant metastases. The manufacturer provided one study for the purpose of this assessment.

In 2018, IQWiG looked into whether dabrafenib plus trametinib, when compared with watchful waiting, has any advantages or disadvantages for people who have had surgery to completely remove melanoma with a BRAF V600 mutation and lymph node metastases. Here, too, the manufacturer provided one study for the purpose of this assessment.

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of dabrafenib (Tafinlar) and trametinib (Mekinist).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Trametinib – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A15-40. December 28, 2015. (IQWiG reports; Volume 354).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dabrafenib (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A15-39. December 28, 2015. (IQWiG reports; Volume 353).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dabrafenib (melanoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-59. December 20, 2018. (IQWiG reports; Volume 696).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Trametinib (melanoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-60. December 20, 2018. (IQWiG reports; Volume 697).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on January 17, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.